<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is likely the third modifiable risk factor for <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> after cigarette smoking and <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Epidemiological investigations have found that long-term type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is associated with a 1.5-fold to 2.0-fold increase in the risk of <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>A causal relationship between <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> is also supported by findings from prediagnostic evaluations of <z:chebi fb="105" ids="17234">glucose</z:chebi> and insulin levels in prospective studies </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> and associated <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo>, and <z:mp ids='MP_0001845'>inflammation</z:mp> have been suggested to be the underlying mechanisms contributing to development of <z:mp ids='MP_0002055'>diabetes</z:mp>-associated <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Signaling pathways that regulate the metabolic process also play important roles in cell proliferation and <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Use of the <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> drug <z:chebi fb="0" ids="6801">metformin</z:chebi> has been associated with reduced risk of <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> in diabetics and recognized as an antitumor agent with the potential to prevent and treat this <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>On the other hand, new-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:mp ids='MP_0002055'>diabetes</z:mp> may indicate subclinical <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo>, and patients with new-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:mp ids='MP_0002055'>diabetes</z:mp> may constitute a population in whom <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> can be detected early </plain></SENT>
<SENT sid="7" pm="."><plain>Biomarkers that help define high-risk individuals for clinical screening for <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> are urgently needed </plain></SENT>
<SENT sid="8" pm="."><plain>Why <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> causes <z:mp ids='MP_0002055'>diabetes</z:mp> and how <z:mp ids='MP_0002055'>diabetes</z:mp> affects the clinical outcome of <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> have yet to be fully determined </plain></SENT>
<SENT sid="9" pm="."><plain>Improved understanding of the pathological mechanisms shared by <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> would be the key to the development of novel preventive and therapeutic strategies for this <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>